AR016957A1 - Derivado de amida y composicion farmaceutica util para la inhibicion del canal de ca2+ activado por liberacion de ca2+ - Google Patents

Derivado de amida y composicion farmaceutica util para la inhibicion del canal de ca2+ activado por liberacion de ca2+

Info

Publication number
AR016957A1
AR016957A1 ARP980105064A ARP980105064A AR016957A1 AR 016957 A1 AR016957 A1 AR 016957A1 AR P980105064 A ARP980105064 A AR P980105064A AR P980105064 A ARP980105064 A AR P980105064A AR 016957 A1 AR016957 A1 AR 016957A1
Authority
AR
Argentina
Prior art keywords
group
substituted
formula
lower alkyl
alkyl groups
Prior art date
Application number
ARP980105064A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR016957A1 publication Critical patent/AR016957A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivado de amida, caracterizado porque está representado por la formula general (I), [los símbolos en la formula tienen los siguientes significados:D representa un grupo pirazolilo que puede tener 1 a 3 grupos alquilo inferior sustituidos o no sustituidos con halogeno como sustituyente(s); B representaun grupo fenileno o tiofenediilo; X representa un grupo de formula -NH-CO- -CO-NH-; y A representa un grupo fenilo que puede ser sustituido por uno o másátomos de halogeno, o un grupo heteroarilomonocíclico de 5 o 6 miembros que puede estar sustituido por uno o más grupos alquilo inferior, con lacondicion de que se excluyan 4-metil-4[((3,5-bis)trifluorometil)-1H-pirazol-1-il]-1,2,3-tiadiazol-5-carboxianilida y 4-cloro-5-(1-metil-5-trifluorometil-1H-pirazol-3-il)tiofeno-2-carboxianilida o una sal farmacéuticamente aceptable del mismo. Una composicion farmacéutica que incluye un derivado de amida deformula (I)[los símbolos en la formula tienen los siguientes significados: D representa ungrupo pirazolilo que puede tener 1 a 3 grupos alquilo inferiorsustituidos o no sustituidos con halogeno como sustituyente(s); B representa un grupo fenileno o tiofenediilo; X representa un grupo de formula -NH-CO- o-CO-NH-, y A representa un grupo fenilo que puede ser sustituido por uno o más átomos de halogeno, o un grupo heteroarilo monocíclico de 5 o 6 miembros quepuede estar sustituido por uno o más grupos alquilo inferior y un vehículo farmacéuticamente aceptable, particularmente para ser usada en la inhibiciondel canal Ca2+.
ARP980105064A 1997-10-13 1998-10-13 Derivado de amida y composicion farmaceutica util para la inhibicion del canal de ca2+ activado por liberacion de ca2+ AR016957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27909397 1997-10-13

Publications (1)

Publication Number Publication Date
AR016957A1 true AR016957A1 (es) 2001-08-01

Family

ID=17606326

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105064A AR016957A1 (es) 1997-10-13 1998-10-13 Derivado de amida y composicion farmaceutica util para la inhibicion del canal de ca2+ activado por liberacion de ca2+

Country Status (18)

Country Link
US (4) US6348480B1 (es)
EP (1) EP1024138B1 (es)
KR (1) KR100589868B1 (es)
CN (1) CN1107671C (es)
AR (1) AR016957A1 (es)
AT (1) ATE360618T1 (es)
AU (2) AU751139B2 (es)
BR (1) BR9803883A (es)
CA (1) CA2304979A1 (es)
DE (1) DE69837675T2 (es)
ES (1) ES2285784T3 (es)
HU (1) HUP9802310A1 (es)
NO (1) NO317417B1 (es)
PL (1) PL192411B1 (es)
PT (1) PT1024138E (es)
RU (1) RU2185381C2 (es)
TW (1) TW495498B (es)
WO (1) WO1999019303A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
JP2002521441A (ja) * 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Ｃｃｒ５モジュレーターとしてのプロペンアミド
WO2000006550A1 (fr) * 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Composes phenylazole, procede de production desdits composes et medicaments pour le traitement de l'hyperlipidemie
JP2001031509A (ja) * 1999-07-15 2001-02-06 Nippon Bayer Agrochem Co Ltd チエニル−ピラゾール類の有害生物防除剤としての利用
US6794397B2 (en) * 2000-01-27 2004-09-21 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6451820B1 (en) 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6353007B1 (en) * 2000-07-13 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
EP1186661A1 (en) * 2000-09-05 2002-03-13 Warner-Lambert Company Identification of the major capacitative calcium channel in antigen presenting cells and uses thereof
EP1184457A1 (en) * 2000-09-05 2002-03-06 Warner-Lambert Company Identification of a capacitative calcium channel in antigen presenting cells and uses thereof
WO2002051397A1 (fr) * 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives
WO2002098363A2 (en) * 2001-06-06 2002-12-12 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
ATE372334T1 (de) 2001-06-29 2007-09-15 Boehringer Ingelheim Pharma Phenylpyrazolderivate als seh-inhibitoren
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
CN1325491C (zh) * 2002-08-27 2007-07-11 安斯泰来制药有限公司 新颖结晶
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7790724B2 (en) * 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
WO2005009539A2 (en) * 2003-07-23 2005-02-03 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
PL1706385T3 (pl) 2003-12-23 2011-03-31 Astex Therapeutics Ltd Pochodne pirazolu jako modulatory kinazy białkowej
EA011634B1 (ru) * 2004-03-09 2009-04-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. 3-[4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды в качестве ингибиторов продуцирования цитокинов, предназначенные для лечения хронических воспалительных заболеваний
US7202232B2 (en) * 2004-03-25 2007-04-10 Synta Pharmaceuticals Corp. Acrylonitrile derivatives for inflammation and immune-related uses
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
EP1875925A1 (en) * 2005-04-22 2008-01-09 Astellas Pharma Inc. Preventive or remedy for bowel disease
GB2427406A (en) * 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
EP1984337B1 (en) 2006-01-25 2014-04-30 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
BRPI0708353A8 (pt) 2006-02-28 2017-09-19 Dart Neuroscience Cayman Ltd Compostos terapêuticos
CA2644069A1 (en) 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
US7803799B2 (en) * 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
BRPI0719122A2 (pt) * 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
AU2007291190A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
TWI339205B (en) * 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ580195A (en) * 2007-03-05 2012-03-30 Univ Queensland Targeting crac for breast cancer therapy and/or diagnosis
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
CN104072489B (zh) 2007-08-27 2017-07-07 达特神经科学(开曼)有限公司 治疗用异噁唑化合物
GB0801888D0 (en) * 2008-02-01 2008-03-12 Isis Innovation Treatment of mast cell related disorders
DE102008014523A1 (de) * 2008-03-15 2009-09-17 Robert Bosch Gmbh Heizgerät
CA2724077C (en) * 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound
JP2010030970A (ja) * 2008-07-31 2010-02-12 Bayer Cropscience Ag 殺虫性ベンゼンジカルボキサミド誘導体
TWI434686B (zh) * 2008-11-03 2014-04-21 Nat Health Research Institutes 咪唑－４－酮及咪唑－４－硫酮化合物
MY161598A (en) * 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
EP2440553B1 (en) * 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
JP5916149B2 (ja) 2010-08-27 2016-05-11 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
US9156791B2 (en) 2010-10-21 2015-10-13 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
CA2834928C (en) * 2011-05-03 2017-10-17 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20140256771A1 (en) * 2011-10-19 2014-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2844656A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyrazole compounds as crac modulators
WO2014059333A1 (en) * 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EA201500736A1 (ru) 2013-01-10 2016-04-29 Грюненталь Гмбх Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201500737A1 (ru) 2013-01-10 2016-04-29 Грюненталь Гмбх Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
WO2015017519A1 (en) 2013-07-30 2015-02-05 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
CA2934324A1 (en) * 2013-12-19 2015-06-25 Grunenthal Gmbh Fluoromethyl-substituted pyrrole carboxamides iii
MX2016007951A (es) * 2013-12-19 2016-09-09 Gruenenthal Gmbh Pirrol carboxamidas iv fluorometil-sustituidas.
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
CN107530436B (zh) 2015-01-21 2022-03-29 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
PT3778595T (pt) 2015-02-27 2021-11-09 Calcimedica Inc Tratamento de pancreatite
DK3331525T3 (da) 2015-08-07 2020-12-14 Calcimedica Inc Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade
CN105503832B (zh) * 2015-12-18 2018-03-27 浙江大学 取代吡唑环类衍生物及其用途
US11684584B2 (en) 2016-12-30 2023-06-27 Genevant Sciences Gmbh Branched peg molecules and related compositions and methods
AU2019340601A1 (en) 2018-09-14 2021-05-13 Rhizen Pharmaceuticals A G Compositions comprising a CRAC inhibitor and a corticosteroid and methods of use thereof
CN111187204B (zh) * 2020-01-13 2022-11-08 海利尔药业集团股份有限公司 一种啶虫脒共晶及其制备方法、用途
AU2021228770A1 (en) * 2020-02-28 2022-09-29 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
WO2024126777A1 (en) * 2022-12-16 2024-06-20 Astrazeneca Ab Heteroaromatic compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3401911A1 (de) * 1984-01-20 1985-08-01 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-vinyl-3(2h)-pyridazinone und 6-vinyl-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
GB8409986D0 (en) * 1984-04-17 1984-05-31 Beecham Group Plc Beta-lactam antibacterial agents
ES8608874A1 (es) * 1984-05-29 1986-09-01 Pfizer Un procedimiento para la preparacion de una 2-(1h)-quinolona
JPS6455557A (en) * 1987-08-26 1989-03-02 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0419721Y2 (es) 1987-09-29 1992-05-06
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
JP2867450B2 (ja) 1989-08-17 1999-03-08 吉富製薬株式会社 アルキレンビスアミド化合物
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4126994A1 (de) * 1991-08-16 1993-02-18 Basf Ag (alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen
JP3141261B2 (ja) 1992-10-22 2001-03-05 松下電工株式会社 警報表示器
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JPH07225401A (ja) * 1994-02-14 1995-08-22 Fuji Photo Film Co Ltd 非線形光学材料
AU3577995A (en) * 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
HU223601B1 (hu) * 1995-02-02 2004-10-28 Smithkline Beecham P.L.C. 5-HT receptor antagonista indolszármazékok
AU5426296A (en) * 1995-04-04 1996-10-23 E.I. Du Pont De Nemours And Company Herbicidal heteroaryl-substituted anilides
JPH10507205A (ja) 1995-08-02 1998-07-14 ホータ．ウリアッヒ イ シイア．エセ．アー． 抗真菌活性を有する新規カルボンアミド
JPH1072434A (ja) * 1996-04-08 1998-03-17 Nissan Chem Ind Ltd ２，４−置換アニリン誘導体
WO1998037069A1 (fr) 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Derives d'acide indoldicarboxylique
WO1998037068A1 (en) * 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
DE19708928A1 (de) * 1997-03-05 1998-09-10 Bayer Ag Substituierte aromatische Aminoverbindungen
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US20010044445A1 (en) * 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production

Also Published As

Publication number Publication date
AU8713998A (en) 1999-04-29
TW495498B (en) 2002-07-21
US7247635B2 (en) 2007-07-24
US20010011090A1 (en) 2001-08-02
CN1218046A (zh) 1999-06-02
US6348480B1 (en) 2002-02-19
AU9459398A (en) 1999-05-03
US7285554B2 (en) 2007-10-23
US20060264430A1 (en) 2006-11-23
DE69837675D1 (en) 2007-06-06
ATE360618T1 (de) 2007-05-15
EP1024138B1 (en) 2007-04-25
US6958339B2 (en) 2005-10-25
CN1107671C (zh) 2003-05-07
NO317417B1 (no) 2004-10-25
EP1024138A4 (en) 2002-02-06
PT1024138E (pt) 2007-08-01
ES2285784T3 (es) 2007-11-16
WO1999019303A1 (fr) 1999-04-22
BR9803883A (pt) 2000-05-16
EP1024138A1 (en) 2000-08-02
CA2304979A1 (en) 1999-04-22
US20050234055A1 (en) 2005-10-20
RU2185381C2 (ru) 2002-07-20
PL192411B1 (pl) 2006-10-31
HUP9802310A1 (hu) 2000-03-28
KR100589868B1 (ko) 2006-10-24
NO20001907L (no) 2000-06-09
DE69837675T2 (de) 2008-01-10
PL329150A1 (en) 1999-04-26
AU751139B2 (en) 2002-08-08
NO20001907D0 (no) 2000-04-12
HU9802310D0 (en) 1998-12-28
KR19990037018A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
AR016957A1 (es) Derivado de amida y composicion farmaceutica util para la inhibicion del canal de ca2+ activado por liberacion de ca2+
KR970706813A (ko) 단백질 키나아제의 억제물질로서 유용한 제약용 피라졸 조성물(pharmaceutical pyrazole compositions useful as inhibitors of protein kinases)
AR033306A1 (es) Compuestos
AR107377A2 (es) Compuestos derivados de tetrahidroquinolina
RU98118557A (ru) Амидное производное и фармацевтическая композиция
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
AR023308A1 (es) Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.
ES2183548T3 (es) Dihidropirimidinas.
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
KR910016697A (ko) 테트라히드로피리딘 유도체
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
CO5090848A1 (es) Compuestos de benceno sustituidos, procedimientos para su preparacion, y composiciones herbicidas y de foliantes que los contienen
HUP0303070A2 (hu) 3,4-Dihidro-izokinolin-származékok és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR018159A1 (es) Compuestos derivados de amidin-amino-acidos halogenados utiles como inhibidores de la oxido-nitrico-sintetasa, composicion farmaceutica que los contiene ymetodo de tratamiento
DK0630366T3 (da) Substituerede heterocycliske derivater, der er nyttige som blodpladeaggregeringsinhibitorer
ATE319704T1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
ES2167931T3 (es) Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen.
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
AR021826A1 (es) COMPUESTOS DE 2- FENILPIRAN-4-ONA, PROCESOS PARA PREPARARLOS, USO DE UN COMPUESTO INTERMEDIARIO EN DICHOS, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y USO DE DICHOS COMPUESTOS Y DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO
DE69103968D1 (de) 2-(Aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre Herstellung und ihre Anwendung in der Therapeutik.

Legal Events

Date Code Title Description
FB Suspension of granting procedure